Search company, investor...

Orionis Biosciences

orionisbio.com

Founded Year

2015

Stage

Series B | Alive

Total Raised

$79.5M

Last Raised

$55M | 1 mo ago

About Orionis Biosciences

Orionis Biosciences is a life science company specializing in genome-scale drug discovery and tunable molecular design of therapeutic drug modalities. It targets core disease vulnerabilities with molecular drug interactions. The firm serves clients in the healthcare sector. It was founded in 2015 and is based in Waltham, Massachusetts.

Headquarters Location

950 Winter Street

Waltham, Massachusetts, 02451,

United States

Missing: Orionis Biosciences's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Orionis Biosciences's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Orionis Biosciences Patents

Orionis Biosciences has filed 1 patent.

The 3 most popular patent topics include:

  • Immune system
  • Immunology
  • Transcription factors
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/8/2018

11/15/2022

Clusters of differentiation, Immune system, Monoclonal antibodies, Monoclonal antibodies for tumors, Cancer treatments

Grant

Application Date

8/8/2018

Grant Date

11/15/2022

Title

Related Topics

Clusters of differentiation, Immune system, Monoclonal antibodies, Monoclonal antibodies for tumors, Cancer treatments

Status

Grant

Latest Orionis Biosciences News

Orionis Biosciences Presents Preclinical Data on Interferon and IL-2 Targeted Cytokine Immunotherapies for Cancer

Nov 14, 2022

Company shared progress from its proprietary A-Kine™ platform for engineering of target-selective, cis-acting cytokine immunotherapies at 2022 PEGS Europe Protein and Antibody Engineering Summit Data demonstrate potent single-agent anti-tumor activity of immune cell-targeted interferons and interleukin-2 through remodeling of tumor microenvironments and cancer immunity cycle in syngeneic and humanized mouse models Orionis anticipates IND submission and start of conditionally active cytokine Phase 1 trial in 2023 November 14, 2022 08:00 AM Eastern Standard Time BOSTON & GHENT, Belgium--( BUSINESS WIRE )-- Orionis Biosciences , a life sciences company pioneering innovation of highly selective and tunable therapeutics for cancer and beyond, today presented preclinical data supporting its A-Kine™ platform for rational design of cis-acting immuno-cytokines at the 14th Annual PEGS Europe Protein & Antibody Engineering Summit, taking place November 14 – 16 in Barcelona, Spain. The data demonstrate potent anti-tumor activity across multiple classes of targeted cytokines. Cytokines are powerful regulators of the immune system and attractive therapeutic effector candidates. However, their sites of action must be restricted to avoid systemic toxicity. To achieve spatial control of cytokine bioactivity, Orionis has developed a proprietary biologics platform that integrates a strategic “plug-and-play” assembly of modular biomolecular building blocks into therapeutic agents with unique conditional effector functions and cell-target selectivity. These conditionally active, cis-acting cytokines aim to trigger anti-tumor immune responses even in cold tumors that lack prevalent immune involvement and are refractory to checkpoint inhibitor and other therapies. “Today we shared preclinical data that represent exciting progress for our proprietary A-Kine platform. Our R&D engine, inspired by nature’s intrinsic mechanisms for disease control, has the potential to address some of the biggest challenges in oncology drug discovery and beyond,” said Nikolai Kley, Ph.D., Founder, President and Chief Executive Officer of Orionis Biosciences. “As we look ahead, we anticipate IND submission and the start of a conditionally active cytokine Phase 1 trial in 2023.” Orionis’ deep and diversified A-Kine pipeline comprises multiple cytokine classes, including re-engineered interferons (IFNs), interleukins (ILs) and tumor necrosis factors (TNFs). In conjunction with an arsenal of cell-targeting strategies, Orionis is harnessing the therapeutic potential of these cytokines to reprogram immune cells and reactivate the cancer immunity cycle, and thereby the immune system’s natural mechanisms of disease control. The company presented its advances and breakthroughs in design, engineering and development of exquisitely target-selective A-Kines incorporating: Cis-acting Interferons to promote immune system recognition and infiltration of tumors Cis-acting Interleukin-2 to directly activate CD8+ tumor cytotoxic T cells These unique agents exhibit potent, single agent anti-tumor activity in multiple preclinical cancer models, mediated by targeting of key immune cells, including subtypes of myeloid cells and tumor cytotoxic CD8+ T cells, and PD-1/PD-L1 checkpoint mechanisms. Orionis’ A-Kine pipeline reflects multiple protein engineering innovations and contains an array of programs in lead optimization and IND-enabling phases. Details of today’s presentation are as follows: 14th Annual PEGS Europe Protein & Antibody Engineering Summit, November 14–16, 2022, Barcelona, Spain Title: A-Kine Platform: On-Target Cytokines to Reprogram Cell Targets for Immuno-Oncology Date and Time: Monday, November 14, 11:45 a.m. CET Presenter: Erik Depla, Ph.D., Director of Biology, Orionis Bio Orionis recently announced a $55 million financing to support entry of its lead A-Kine cancer immunotherapy programs into the clinic. The company anticipates IND submission and start of a Phase 1 study of a conditionally active cytokine in 2023. In addition to the A-Kine platform, Orionis has developed the Allo-Glue™ protein degradation platform for discovery and rational design of small molecule molecular glues. These types of conditionally active small molecules are designed to tackle traditionally undruggable or elusive drug targets by harnessing nature’s cellular machinery to degrade and dispose of proteins that cause and/or promote disease. About Orionis Biosciences Orionis Biosciences is a life sciences company pioneering technological innovations in genome-scale drug discovery to develop novel, highly specific and tunable therapeutics for cancer and beyond. The company utilizes its proprietary A-Kine™ biologics and Allo-Glue™ small molecule platforms to target core disease vulnerabilities and reach previously intractable targets. Orionis has multiple first-in-class immunotherapies in development for the treatment of cancer. Learn more at www.orionisbio.com . Contacts

Orionis Biosciences Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Orionis Biosciences Rank

Orionis Biosciences Frequently Asked Questions (FAQ)

  • When was Orionis Biosciences founded?

    Orionis Biosciences was founded in 2015.

  • Where is Orionis Biosciences's headquarters?

    Orionis Biosciences's headquarters is located at 950 Winter Street, Waltham.

  • What is Orionis Biosciences's latest funding round?

    Orionis Biosciences's latest funding round is Series B.

  • How much did Orionis Biosciences raise?

    Orionis Biosciences raised a total of $79.5M.

  • Who are the investors of Orionis Biosciences?

    Investors of Orionis Biosciences include Novartis, Cormorant Asset Management and Excel Venture Management.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.